"Androstenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
| Descriptor ID |
D000736
|
| MeSH Number(s) |
D04.210.500.054.079
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Androstenes".
Below are MeSH descriptors whose meaning is more specific than "Androstenes".
This graph shows the total number of publications written about "Androstenes" by people in this website by year, and whether "Androstenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 3 | 5 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androstenes" by people in Profiles.
-
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer Med. 2023 08; 12(15):16490-16501.
-
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
-
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Support Care Cancer. 2022 Mar; 30(3):2803-2810.
-
The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check. JAMA Oncol. 2021 06 01; 7(6):827-828.
-
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021 06; 150:83-94.
-
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088.
-
Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer. Cancer. 2020 12 01; 126(23):5050-5059.
-
Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020 09; 374(3):438-451.
-
Adoption of Abiraterone and Enzalutamide by Urologists. Urology. 2019 09; 131:176-183.
-
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol. 2019 05 01; 37(13):1120-1129.